Literature DB >> 26379937

Effect of obesity and hyperglycemia on benign prostatic hyperplasia in elderly patients with newly diagnosed type 2 diabetes.

Zhe Chen1, Li Miao1, Xia Gao1, Guang Wang1, Yuan Xu1.   

Abstract

PURPOSE: To investigate the relationship between blood glucose levels, age, body mass index (BMI), and benign prostatic hyperplasia (BPH) in patients with newly diagnosed type 2 diabetes.
METHODS: A total of 141 BPH patients with newly diagnosed type 2 diabetes participated in this study. Their glucose level, international prostate symptom score (IPSS), prostate volume (PV), and maximum urinary flow rate (Qmax) were determined and analyzed.
RESULTS: Compared to patients in 60-69 years of age, those in 70-79 years of age had higher IPSS and PV values (11.10±2.68 vs. 16.09±2.64, respectively; P<0.01; 38.67±4.65 vs. 44.76±2.84, respectively; P<0.01) as did patients ≥80 y (11.10±2.68 vs. 19.87±3.35, respectively; P<0.01; 38.67±4.65 vs. 51.38±3.74, respectively; P<0.01). The Qmax was lower in the ≥80 y group compared to the 60-69 y group (7.91±2.13 vs. 13.50±1.75, respectively; P<0.01). IPSS, PV, and insulin resistance index (HOMA-IR) were higher in patients with a BMI ≥28 kg/m(2) group as compared to those with a BMI <24 kg/m(2) group. IPSS and PV values were higher in patients with HbA1c levels ≥6.5% than in those with HbA1c<6.5% (16.30±3.31 vs. 9.87±1.07, respectively; P<0.01; 45.69±3.97 vs. 36.64±3.30, respectively; P<0.01), and the Qmax was lower (10.61±1.98 vs. 14.40±0.82, respectively; P<0.01).
CONCLUSIONS: Aging, obesity, high glucose level, and insulin resistance increase the risk of BPH progression in elderly patients with newly diagnosed type 2 diabetes. Managing body weight and lowering the level of glycosylated hemoglobin may slow the progression of BPH in people with type 2 diabetes.

Entities:  

Keywords:  Type 2 diabetes mellitus; benign prostatic hyperplasia; blood glucose level; obesity

Year:  2015        PMID: 26379937      PMCID: PMC4565320     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  17 in total

Review 1.  Benign prostatic hyperplasia: dietary and metabolic risk factors.

Authors:  H Nandeesha
Journal:  Int Urol Nephrol       Date:  2008-02-02       Impact factor: 2.370

Review 2.  Benign prostatic hyperplasia: a new metabolic disease?

Authors:  L Vignozzi; G Rastrelli; G Corona; M Gacci; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2014-01-24       Impact factor: 4.256

3.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

Review 4.  The correlation between metabolic syndrome and prostatic diseases.

Authors:  Cosimo De Nunzio; William Aronson; Stephen J Freedland; Edward Giovannucci; J Kellogg Parsons
Journal:  Eur Urol       Date:  2011-11-15       Impact factor: 20.096

Review 5.  PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Authors:  Ming Jiang; Douglas W Strand; Omar E Franco; Peter E Clark; Simon W Hayward
Journal:  Differentiation       Date:  2011-06-08       Impact factor: 3.880

6.  Hypertension, diabetes mellitus, and blood groups in benign prostatic hypertrophy.

Authors:  J B Bourke; J P Griffin
Journal:  Br J Urol       Date:  1966-02

Review 7.  Insulin-resistance and benign prostatic hyperplasia: the connection.

Authors:  Ajit Vikram; Gopabandhu Jena; Poduri Ramarao
Journal:  Eur J Pharmacol       Date:  2010-06-09       Impact factor: 4.432

8.  Central obesity as a risk factor for prostatic hyperplasia.

Authors:  Sangyeoup Lee; Hong Gi Min; Sang Han Choi; Yun Jin Kim; Sang Woo Oh; Young Joo Kim; Yongsoon Park; Sung Soo Kim
Journal:  Obesity (Silver Spring)       Date:  2006-01       Impact factor: 5.002

9.  IL-1 induces IGF-dependent epithelial proliferation in prostate development and reactive hyperplasia.

Authors:  Travis J Jerde; Wade Bushman
Journal:  Sci Signal       Date:  2009-09-01       Impact factor: 8.192

10.  Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors.

Authors:  J Kellogg Parsons
Journal:  Curr Bladder Dysfunct Rep       Date:  2010-09-07
View more
  8 in total

1.  Is there room for behavioral and modifiable health-related targets in the lower urinary tract symptoms' scenario.

Authors:  Osamu Ikari; Brunno C F Sanches; João Carlos Cardoso Alonso; Fabiano A Simões; Ronald F Rejowski; Walker Wendel Laranja; Leonardo O Reis
Journal:  World J Urol       Date:  2017-01-25       Impact factor: 4.226

2.  Serum testosterone and prostate-specific antigen levels are major risk factors for prostatic volume increase among benign prostatic hyperplasia patients.

Authors:  Gede Wirya Kusuma Duarsa; Yudit Anastasia Sari; Anak Agung Gde Oka; Kadek Budi Santosa; I Wayan Yudiana; Pande Made Wisnu Tirtayasa; Ida Bagus Putra Pramana; Yudhistira Pradnyan Kloping
Journal:  Asian J Urol       Date:  2020-06-07

3.  High glucose induces the proliferation of prostatic cells via downregulating MRE11.

Authors:  Chunwei Ye; Yi Cai; Qian Cai; Shunhui Yuan; Fan Huang; Xiaofang Yang; Shuchen He; Zhuoheng Li; Yanwen Wang; Delin Yang; Zhipeng Li
Journal:  Int J Mol Med       Date:  2018-03-07       Impact factor: 4.101

4.  Metformin inhibits the proliferation of benign prostatic epithelial cells.

Authors:  Zongwei Wang; Xingyuan Xiao; Rongbin Ge; Jijun Li; Cameron W Johnson; Cyrus Rassoulian; Aria F Olumi
Journal:  PLoS One       Date:  2017-03-02       Impact factor: 3.240

5.  Correlation of self-reported urologic symptoms with systemic health conditions in minority men.

Authors:  Sarah Coleman Vij; Andrew Turk; Tianming Gao; Daniel A Shoskes
Journal:  Transl Androl Urol       Date:  2017-10

6.  Body Mass Index and Risk of Prostate Volume, International Prostate Symptom Score, Maximum Urinary Flow Rate, and Post-Void Residual in Benign Prostatic Hyperplasia Patients.

Authors:  Bing-Hui Li; Tong Deng; Qiao Huang; Hao Zi; Hong Weng; Xian-Tao Zeng
Journal:  Am J Mens Health       Date:  2019 Jul-Aug

7.  A synchronous spectrofluorometric technique for simultaneous detection of alfuzosin and tadalafil: applied to tablets and spiked biological samples.

Authors:  Heba Samir Elama; Shereen M Shalan; Yasser El-Shabrawy; Manal I Eid; Abdallah M Zeid
Journal:  R Soc Open Sci       Date:  2022-07-13       Impact factor: 3.653

8.  Correlation between body mass index and prostate volume in benign prostatic hyperplasia patients undergoing holmium enucleation of the prostate surgery.

Authors:  Ken Batai; Michael Phung; Robert Bell; Aye Lwin; Kieran A Hynes; Elinora Price; Karleen M Meiklejohn; Erika R Bracamonte; Joel T Funk
Journal:  BMC Urol       Date:  2021-06-10       Impact factor: 2.264

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.